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Abstract 25 
 26 
Context 27 
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD), resulting from activating 28 
mutations in the arginine vasopressin receptor type 2 (AVPR2) is a rare cause of 29 
hyponatraemia.  However, its true prevalence may be under-estimated and it should be 30 
considered in the investigation of unexplained hyponatraemia, with implications for 31 
management and targeted gene testing. 32 
 33 
Objective 34 
We describe a structured approach to the investigation of hyponatraemia in a young patient, 35 
which allowed a diagnosis of NSIAD to be made.  We review current knowledge of NSIAD, 36 
and use a structural modelling approach to further our understanding of the potential 37 
mechanisms by which the causative mutation leads to a constitutively active AVPR2. 38 
 39 
Design 40 
Clinical and biochemical investigation of hyponatraemia; a formal water load test with 41 
measurement of arginine vasopressin levels (AVP); sequencing of AVPR2; and computed 42 
structural modelling of the wild-type and constitutively activated mutant receptors. 43 
 44 
Results 45 
A 38-year-old man presented with intermittent confusion and nausea associated with 46 
hyponatraemia and a biochemical picture consistent with syndrome of inappropriate 47 
antidiuretic hormone (SIADH).  Adrenocortical and thyroid function, and an acute 48 
intermittent porphyria screen were normal.  Cross-sectional imaging of the head, chest and 49 
abdomen did not identify an underlying cause and so we proceeded to a water load test.  This 50 
demonstrated a marked inability to excrete a free water load (just 15% of a 20 mL/kg oral 51 
load by 240 mins post-ingestion), with the onset of hyponatraemia (Na+ 125 mmol/L, urine 52 
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osmolality 808 mOsm/kg).  However, AVP levels were low throughout the test (0.4-0.9 53 
pmol/L), consistent with a diagnosis of NSIAD.  AVPR2 sequencing revealed a previously 54 
described hemizygous activating mutation (p.Arg137Cys).  Through structural modelling of 55 
AVPR2, we suggest the disruption of a hydrogen bond between residues Thr269 and Arg137 56 
may promote stabilisation of the receptor in its active conformation. Since diagnosis, the 57 
patient has adhered to modest fluid restriction and remained well, with no further episodes of 58 
hyponatraemia.   59 
 60 
Conclusion 61 
NSIAD should be considered in young patients with unexplained hyponatraemia.  A water 62 
load test with AVP measurement is a potentially informative investigation, while AVPR2 63 
sequencing provides a definitive molecular genetic diagnosis and a rationale for long-term 64 
fluid restriction. 65 
66 
 4 
Introduction 67 
Hyponatraemia is relatively common, affecting 15-20% of hospital inpatients, and is 68 
associated with increased morbidity and mortality1-5.  The aetiology is frequently 69 
multifactorial2.  Once pseudo-hyponatraemia, factitious causes and hyperosmolar/dilutional 70 
hyponatraemia have been excluded, there remains the broad category of hypoosmolar 71 
hyponatraemia, which may be sub-classified by volume status6. Hypervolaemic and 72 
hypovolaemic hyponatraemia complicate excessive water retention or water and sodium loss 73 
respectively.  Euvolaemic hyponatraemia is associated with diminished free water excretion; 74 
the accompanying expansion in circulating volume is partially counter-acted by suppression 75 
of plasma renin and aldosterone, which in turn exacerbates the hyponatraemia.  The most 76 
common cause is the syndrome of inappropriate antidiuresis (SIAD) due to inappropriate 77 
release of arginine vasopressin (AVP) – i.e. the syndrome of inappropriate antidiuretic 78 
hormone (SIADH).  Recent European Society of Endocrinology guidelines conclude that a 79 
diagnosis of SIAD in the context of hyponatraemia requires: i) effective serum osmolality 80 
<275 mOsm/kg, ii) urine osmolality >100 mOsm/kg at some level of decreased effective 81 
osmolality, iii) clinical euvolaemia, iv) urine sodium concentration >30 mmol/L with normal 82 
dietary salt and water intake, v) absence of adrenal, thyroid, pituitary or renal insufficiency 83 
and vi) no recent use of diuretic drugs7.  SIADH may arise in the context of neoplasia, 84 
neurological disorders, lung disease, infections, treatment with a variety of drugs and other 85 
miscellaneous conditions including acute intermittent porphyria and ectopic AVP production.  86 
This leaves a proportion of cases labelled as ‘idiopathic’.  The incidence of such cases 87 
increases with age8 and SIADH per se is very uncommon in children9. 88 
 89 
Recently, Feldman and colleagues described two paediatric patients with hyponatraemia, both 90 
of whom met the criteria for SIAD but in the absence of a classical cause10.  Furthermore, 91 
AVP was undetectable and subsequent molecular genetic studies identified mutations at 92 
codon 137 (p.Arg137Cys and p.Arg137Leu) that render the arginine vasopressin receptor type 93 
2 (AVPR2) constitutively active, thereby mediating downstream actions of AVP, including 94 
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water reabsorption, in the absence of ligand binding. This monogenic ‘nephrogenic’ 95 
syndrome of inappropriate antidiuresis (NSIAD) has since been described in a small number 96 
of kindreds, including adult cases, with a markedly heterogeneous phenotype.    97 
 98 
Here, we report a case of intermittent hyponatraemia in a 38-year-old man with clinical and 99 
biochemical findings consistent with SIADH.  Given the relative rarity of this diagnosis in his 100 
age group and the lack of an obvious precipitant, we performed a water load test with AVP 101 
measurement, which suggested a diagnosis of NSIAD.  This was subsequently confirmed by 102 
sequencing of AVPR2 and demonstration of the p.Arg137Cys mutation, with structural 103 
modelling offering novel insights into the molecular basis for constitutive activation by the 104 
mutant receptor.  We further discuss the implications for management of the patient in the 105 
context of a diagnosis of NSIAD. 106 
107 
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Materials and Methods 108 
All studies were performed in accordance with local standard clinical practice. 109 
 110 
Biochemical analyses 111 
All analytes were measured by a United Kingdom Accreditation Service (UKAS, Middlesex, 112 
UK) accredited laboratory with relevant internal and external quality assurance as 113 
recommended by the UKAS. Thyrotropin (TSH) was measured by chemiluminescent 114 
immunometric assay using a Siemens Centaur®  immuno-analyser (Siemens Healthcare, 115 
Surrey, UK) with protocols and reagents provided by the manufacturer.  Serum free thyroxine 116 
was measured using a one-step chemiluminescent analogue method on the Centaur® using 117 
reagents provided by the same manufacturer.  Cortisol was measured by competitive 118 
chemiluminescent immunoassay also using the Centaur®. Serum Na+, K+, Ca2+, glucose and 119 
urea, and urine Cr and Na+ were measured using a Siemens ADVIA 2400 using protocols and 120 
reagents provided by the manufacturer.  Whole blood sodium was also measured using a 121 
B221 blood gas analyser using equipment, protocols and reagents provided by Roche 122 
Diagnostics (Sussex, UK).  Blood glucose was also measured using a Nova Biomedical 123 
StatStrip™ blood glucose monitoring system (Nova Biomedical Cheshire, UK). Serum and 124 
urine osmolalities were measured using an Advanced micro-osmometer 3300 (Advanced 125 
instruments inc. Mass, US).  Plasma aldosterone was measured using liquid chromatography 126 
tandem mass spectrometry, adapted from a previously published protocol11 using an AB 127 
SCIEX 5500 (AB Sciex UK Ltd, Cheshire, UK) and validated to UKAS standards.  Plasma 128 
renin concentration was measured using an immunometric assay on a Liason XL® analyser 129 
with reagents and protocols provided by Diasorin (Kent, UK).  Plasma AVP was measured by 130 
the Newcastle (UK) SAS laboratory with an in-house radio-immunoassay method using C18 131 
resin-extracted plasma and a 125I-labelled AVP tracer.  Urine PBG was measured using a PBG 132 
by Column Test provided by Biorad (Herts UK).  133 
 134 
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Water load test 135 
A dynamic water load test was adapted from a published protocol12.  Briefly, this comprises a 136 
body mass adjusted oral water load (20 mL/kg) ingested over 15 minutes, followed by a 137 
period of observation during which time urine output and biochemical responses are 138 
measured. The patient is fasted overnight and should abstain from caffeine and smoking, but 139 
is allowed moderate free fluid intake.  Following cannulation and weight measurement, the 140 
patient fully voids their bladder before resting for 30 minutes.  Baseline bloods are drawn for 141 
measurement of Na+, K+, urea, serum osmolality and AVP, and  point of care venous blood 142 
gas analysis for Na+ and glucose.  A urine sample is collected for osmolality measurement.   143 
The point of care Na+ analysis allows for real time assessment of natraemic status; the water 144 
load should not proceed if there is significant hyponatraemia at baseline.  The patient then 145 
drinks the oral free water load. Further samples are taken at 60, 120, 180 and 240 minutes, 146 
along with a paired urine output volume record.  Further measurements are taken over the 147 
predicted ‘recovery’ phase at 300 and 360 minutes.  Persistent hyponatraemia at this stage 148 
mandates a period of inpatient observation.  It has been reported that normal subjects excrete 149 
78-82% of the ingested water load by 240 minutes, which can be reduced to 30-40% in 150 
patients with syndrome of inappropriate antidiuresis12.  In AVP-mediated SIAD, serum AVP 151 
levels fail to suppress at serum osmolalities below the standard normal threshold for AVP 152 
release (275-285 mOsm/kg)12.  To exclude urinary retention, an ultrasound scan of the bladder 153 
was performed at the bedside at the conclusion of the test, to determine residual volume. 154 
 155 
Genetic sequencing 156 
Genomic DNA was extracted from peripheral blood lymphocytes. The coding region of 157 
AVPR2 was then amplified by PCR of genomic DNA and sequenced by conventional Sanger 158 
sequencing using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 159 
Paisley, UK) and analysed on an ABI 3730 automated sequencer (Applied Biosystems, 160 
Paisley, UK).  Primer sequences are available on request. 161 
 162 
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Structural modelling 163 
The AVPR2 structural models for each of the wild-type and mutant receptors were generated 164 
using the Phyre2 (Protein Homology/analogY Recognition Engine 2) web portal, which 165 
predicts and analyses protein structures for a submitted amino acid sequence based on 166 
homology/analogy recognition to solved protein crystal structures, and MacPymol, a 167 
molecular graphics program for visualisation and analysis of 3D structures13. 168 
169 
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Results 170 
 171 
Case history and baseline biochemistry 172 
A 38-year-old man presented to his local Emergency Department with confusion and a brief 173 
loss of consciousness.  He denied any intake of alcohol and reported that he had only drunk a 174 
moderate amount of fluid in the preceding 24 hours.  There was no history of intercurrent 175 
illness or illicit drug use.  His past medical history included depression treated with 176 
citalopram, and asthma, for which he used salbutamol and budesonide/formeterol inhalers.  177 
No collateral history was available with respect to his early childhood.  Systemic enquiry did 178 
not reveal any other issues and there was no relevant family history.  Physical examination 179 
was otherwise unremarkable.  His serum sodium at presentation was 117 mmol/L [reference 180 
range (RR) 135-145].  Initial management in the Emergency Department was with 0.9% 181 
sodium chloride intravenously, which failed to resolve his hyponatraemia; 24 h later his 182 
sodium was 115 mmol/L.  He was discharged with oral ‘slow sodium’ and his citalopram was 183 
discontinued.  He was admitted on several other occasions over the next six months with 184 
stereotyped episodes of malaise, nausea and confusion, with serum sodium often below 120 185 
mmol/L.  Between admissions, his sodium was reported to be within normal limits.  There did 186 
not appear to be a specific trigger for the periods of illness and he reported a broadly matched 187 
fluid intake and urine output with ‘average’ thirst. 188 
 189 
At his first Endocrine Clinic review following tertiary referral, he was lucid, felt well and his 190 
biochemistry was unremarkable [serum Na+ 134 mmol/L (RR 135-145), serum K+ 4.4 191 
mmol/L (RR 3.4-5.0), plasma glucose 5.0 mmol/L, serum urea 5.3 mmol/L (RR 0-7.5), serum 192 
creatinine 87 µmol/L (RR 35-125), serum osmolality 282 mOsm/kg (RR 280-300), urine 193 
osmolality 799 mOsm/kg and urine Na+ 189.6 mmol/L].  In marked contrast, at his second 194 
appointment six weeks later, he appeared mildly confused and was nauseated.  He was 195 
clinically euvolaemic and normotensive with no postural drop in blood pressure (lying 130/80 196 
mmHg, standing 135/85 mmHg).  Investigation confirmed hyponatraemia with a clinical and 197 
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biochemical picture consistent with syndrome of inappropriate antidiuresis [serum Na+ 124 198 
mmol/L (RR 135-145), serum K+ 4.5 mmol/L (RR 3.4-5.0), plasma glucose 6.0 mmol/L, 199 
serum urea 4.7 mmol/L (RR 0-7.5), serum creatinine 76 µmol/L (RR 35-125), serum 200 
osmolality 268 mOsm/kg (RR 280-300), urine osmolality 652 mOsm/kg and urine Na+ 153.6 201 
mmol/L].   202 
 203 
Further biochemistry 204 
The patient declined admission but agreed to further investigation.  Thyroid and 205 
adrenocortical function were normal [serum free T4 14.4 pmol/L (RR 10-19.8), serum TSH 206 
1.1 mU/L (RR 0.35-5.5), 9 am serum cortisol 501 nmol/L, 30 min post-Synacthen® serum 207 
cortisol 714 nmol/L (RR >450), plasma renin 27 mU/L (RR 5.4-60)] and plasma aldosterone 208 
292 pmol/L (RR 100-800)].  Serum corrected Ca2+ [2.3 mmol/L (RR 2.1-2.5)] and plasma 209 
HbA1c [32 mmol/mol (RR 30-45)] were also within normal limits.  A contemporaneous 210 
screen for acute intermittent porphyria was normal [urine porphobilinogen 4.2 µmol/L (RR 0-211 
10.2), urine porphobilinogen:creatinine ratio 0.7 mmol/mol (RR 0-1.5)]. 212 
 213 
At his next review one week later, his symptoms and hyponatraemia had both resolved 214 
without intervention [serum Na+ 135 mmol/L (RR 135-145), serum K+ 4.0 mmol/L (RR 3.4-215 
5.0), plasma glucose 5.3 mmol/L, serum urea 5.3 mmol/L (RR 0-7.5), serum creatinine 97 216 
µmol/L (RR 35-125), serum osmolality 281 mOsm/kg (RR 280-300), urine osmolality 717 217 
mOsm/kg and urine Na+ 131 mmol/L]. 218 
 219 
Imaging 220 
A plain chest radiograph, computed tomography of the chest, abdomen and pelvis, and 221 
magnetic resonance imaging of the head were all unremarkable. 222 
 223 
Water load test 224 
 11 
Given the intermittent nature of his hyponatraemia, which was consistent with relapsing and 225 
remitting SIAD, but without an identifiable cause for SIADH, a water load test with AVP 226 
measurements was performed (Table 1).  Baseline biochemistry was unremarkable other than 227 
a mild degree of hyponatraemia [venous gas Na+ 133.9 mmol/L (RR 135-148), serum 228 
osmolality 274 mOsm/kg (RR 280-300), urine osmolality 805 mOsm/kg].  Following an oral 229 
load of 20mL/kg (1510 mL) water, taken over 15 minutes, hyponatraemia developed with a 230 
nadir at 180 mins post-ingestion.  His biochemistry at this stage was commensurate with a 231 
syndrome of inappropriate antidiuresis [venous gas Na+ 125.3 mmol/L (RR 135-148), urine 232 
osmolality 808 mOsm/kg].  His urine output was consistent with this, demonstrating a failure 233 
to clear the water load, with a total urine output of just 15% of the ingested fluid at 240 mins, 234 
compared with an expected value of 78-82% in normal subjects12.  Urinary retention was 235 
excluded with a bladder scan, which demonstrated a residual volume of just 77 mL.  Serum 236 
AVP levels were in the low physiological range throughout the test (0.4–0.9 pmol/L).  Urine 237 
osmolality (745-840 mOsm/kg) was persistently elevated.  Together, these findings were 238 
consistent with an AVP-independent (nephrogenic) syndrome of inappropriate antidiuresis. 239 
 240 
Sequencing of arginine vasopressin receptor type 2 (AVPR2) 241 
Analysis of the AVPR2 gene, which is situated on the X chromosome, demonstrated a 242 
hemizygous mutation, with a substitution of cytosine to thymine at nucleotide 770 leading to 243 
a single amino acid change, p.Arg137Cys, which has been previously reported as an 244 
activating mutation causing nephrogenic syndrome of inappropriate antidiuresis10.  This is a 245 
highly conserved residue in AVPR2 across species (Fig. 1a) and across G-protein coupled 246 
receptors in general14, 15. 247 
 248 
Structural modelling of AVPR2 249 
In silico structural modelling of the AVPR2 receptor in both Arg137 and p.Arg137Cys forms 250 
identified a putative hydrogen bond between residues Arg137 and Thr269 in the second 251 
intracellular loop of the G-protein coupled receptor (GPCR) (Fig. 1b, 1c), which is not 252 
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present in the mutant form (p.Arg137Cys).  We speculate that loss of this interaction may 253 
permit adoption of an activated form of the receptor, independent of AVP ligand binding. 254 
255 
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Discussion 256 
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) resulting from constitutive 257 
activation of AVPR2 was first described by Feldman and colleagues in 200510.  Both 258 
probands in the original report presented in infancy (<3 months of age), the first with 259 
irritability and the second with generalised seizures.  In each case, the biochemical picture 260 
was consistent with a syndrome of inappropriate antidiuretic hormone release.  However, 261 
SIADH is a rare occurrence in the paediatric population (Huang and colleagues identified just 262 
13 published cases between 1954 and 2004)9.  Moreover, Feldman et al were unable to 263 
identify a classical cause for SIADH in their subjects, and AVP was subsequently found to be 264 
undetectable in both cases.   265 
 266 
A central step in salt and water homeostasis is the signalling of AVP via its renal G-protein 267 
coupled receptor AVPR2.  Ligand binding and activation leads to cAMP-mediated 268 
recruitment of aquaporin-2 channels to the luminal membrane of the medullary collecting 269 
duct, leading to reabsorption of water and urine concentration.  Inactivating mutations in 270 
AVPR2 are a well recognised cause of nephrogenic diabetes insipidus, with reduced AVPR2-271 
mediated transactivation resulting in diminished cAMP production and thus aquaporin 272 
translocation16.  Point mutations leading to constitutive activation of a GPCR are rarer in 273 
biology than inactivating mutations, but there is precedent in GPCRs involved in other 274 
endocrine signalling pathways, e.g. TSH receptor, luteinising hormone receptor and calcium 275 
sensing receptor17,18,19.  As such, activating mutations in AVPR2 are therefore an obvious 276 
candidate to explain inappropriate antidiuresis occurring independently of AVP. One of the 277 
original mutations identified by Feldman and co-workers was the same as that demonstrated 278 
in our case, p.Arg137Cys, while the second resulted in a different substitution at the same 279 
codon (p.Arg137Leu)10.  Arginine 137 is highly conserved in AVPR2 across species (Fig. 1a) 280 
and is situated in the DRY/H domain of the second intracellular loop, at its juncture with the 281 
third intra-membrane domain, which is highly conserved across the broader GPCR family.  282 
This region appears to play a central role in stabilisation of the receptor in either its active or 283 
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inactive form14,15.  The importance of this particular residue in AVPR2 signalling is confirmed 284 
by the demonstration that an alternative substitution at the same residue, p.Arg137His, 285 
produces an inactivating mutation with resultant nephrogenic diabetes insipidus.  286 
Interestingly, in the basal state the inactivating mutation induces similar basal cAMP 287 
production to its wild type counterpart, which contrasts markedly with the 4–7.5-fold higher 288 
level of transcriptional activity seen with the constitutive activating mutations, p.Arg137Cys 289 
and p.Arg137Leu10.  Rochdi et al have also shown that AVP binding to the p.Arg137Cys and 290 
p.Arg137Leu mutant receptors does not produce a further increase in cellular cAMP or CRE-291 
luciferase reporter assay activity over their already elevated basal levels, nor do inverse 292 
agonists have any effect20, findings which have been replicated by others21.  Together, these 293 
observations suggest that the GPCR complex is ‘locked’ in an active form in the presence of 294 
such mutations, and a change in the interaction between the GPCR Gαs subunit and β-295 
arrestin2 has been postulated to underlie this20.  Carpentier and coworkers have recently used 296 
structural modelling to demonstrate that the relative positioning of the AVPR2 297 
transmembrane helices is altered in another constitutively active form (p.Phe229Val) of the 298 
receptor22.  Extending these findings, we have now identified a putative hydrogen bond 299 
between Arg137 and Thr269 in the second intracellular loop of the wild-type AVPR2 that is 300 
not present in the p.Arg137Cys mutant (Fig. 1b, 1c), and speculate that disruption of this 301 
interaction contributes to the structural change(s) required to allow constitutive activation in 302 
the absence of AVP.  However, additional molecular studies would be required to formally 303 
test this hypothesis. 304 
 305 
To date, fewer than 30 cases of NSIAD due to activating AVPR2 mutations have been 306 
reported10, 23-32.  Whilst the majority of affected individuals harbour mutations at codon 137, 307 
activating mutations affecting other amino acids (p.Phe299Val and p.Ile130Asn) have also 308 
been described22, 33.  It is interesting to note the marked heterogeneity with respect to age at 309 
diagnosis and severity of the disorder between subjects.  For example, several probands 310 
presented with neonatal seizures in the context of hyponatraemia but, on screening family 311 
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members, causative mutations and abnormal water load test dynamics were also observed in 312 
otherwise apparently unaffected individuals.  Accordingly, it seems that a subgroup of those 313 
with activating AVPR2 mutations only come to attention in adult life after an unusually 314 
severe water load or in the context of exogenous salt loss27, suggesting there may be a 315 
protective element of chronic voluntary fluid restriction in these subjects30.  Importantly, 316 
female subjects harbouring heterozygous activating AVPR2 mutations have also been 317 
reported to exhibit reduced water excretion in response to an oral load, and may thus be 318 
similarly affected to some male hemizygotes25, 30, 32.  319 
 320 
Fluid restriction is the mainstay of treatment for NSIAD and can be effective in attenuating 321 
the risk of hyponatraemia, as in our patient.  Oral urea, which reduces natiuresis while 322 
maintaining aquaresis, is an alternative, especially in paediatric cases where strict fluid 323 
restriction may be hazardous or difficult to achieve9,10,23,24,25,27,28,30,31.  Oral sodium 324 
supplementation has been used in some patients, while furosemide has been suggested as an 325 
alternative for refractory cases25.  Inverse agonists (e.g. the vaptan class of drugs) have been 326 
shown to be ineffective in vitro against the p.Arg137Cys and p.Arg137Leu variants20,21, and 327 
indeed one individual harbouring the p.Arg137Cys mutation was identified through a failure 328 
to respond to tolvaptan and satavaptan in the phase III trials of these oral inhibitors25.  Of note 329 
however, the more recently described p.Phe299Val and p.Ile130Asn mutant forms of AVPR2 330 
appear to behave differently.  Phe299 is located at the base of the 5th GPCR transmembrane 331 
domain and in vitro studies demonstrated a marked (30-fold) increase in basal cAMP 332 
production when compared to the wild-type receptor22.  Unlike the Arg137 variants however, 333 
constitutive signalling is abrogated with vaptan treatment, suggesting that the p.Phe299Val 334 
mutation does not permanently lock the receptor in an active configuration.  It has been 335 
postulated that this may be related to the lack of constitutive β-arrestin recruitment to the 336 
receptor, which is present with the Arg137 mutants22.  Similar in vitro findings and response 337 
to vaptan treatment have been described for the p.Ile130Asn activating mutation.  Together, 338 
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these findings raise the possibility of targeted therapy for a subset of NSIAD patients and 339 
highlight the value of confirming a molecular genetic diagnosis. 340 
 341 
The true prevalence of nephrogenic SIAD is uncertain.  One study screened the R137 codon 342 
of AVPR2 in two large cohorts of asymptomatic individuals (i.e. ‘normal’ populations).  A 343 
number of those screened had serum sodium levels below the population reference range.  344 
Genotyping failed to detect any variants at R137 in these cohorts, leading the investigators to 345 
conclude that NSIAD-associated AVPR2 variants are exceedingly uncommon34.  It is possible 346 
though that NSIAD may be more common than is implied by this or by the low number of 347 
reported cases to date, and that cases may be more readily identified by screening 348 
symptomatic hyponatraemic patients, particularly those in whom no obvious cause for 349 
SIADH is identified.  Some support for this notion is provided by historical studies which 350 
identified a subset of patients (14% of a cohort meeting biochemical criteria for SIADH) who 351 
could neither maximally dilute their urine nor excrete a water load normally, in the absence of 352 
any detectable abnormality in vasopressin secretion.  This has been termed  353 
‘hypovasopressinemic antidiureses’ or ‘type D’ SIAD and it has been suggested that the 354 
pathology in these cases reflects either an increase in renal sensitivity to low concentrations of 355 
AVP, or the action of another antidiuretic factor12, 35, 36.  While these early studies have their 356 
limitations, which do not permit distinction between these possibilities, it is tempting to 357 
speculate that nephrogenic SIAD accounts for a proportion of these cases.   358 
 359 
The suspicion of nephrogenic SIAD in our patient was raised by his relatively young age, the 360 
intermittent nature of the hyponatraemia, and the absence of a classical cause for SIADH or 361 
other causes of hyponatraemia despite meeting the diagnostic criteria for SIAD.  We would 362 
advocate considering the diagnosis of NSIAD in such individuals.  Whilst a water load test is 363 
seldom required for a diagnosis of SIAD, by including measurement of AVP, we were able 364 
show in this case that a markedly reduced water clearance and the development of dilutional 365 
hyponatraemia were associated with AVP levels persistently in the low physiological range.  366 
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These levels, in the context of a paradoxical markedly elevated urine osmolality (which serves 367 
as a bioassay for AVP activity) were consistent with NSIAD due to constitutive AVPR2 368 
activation and led us to perform the confirmatory genetic testing (Table 1).   369 
 370 
Finally, there are significant benefits for the patient in making the diagnosis of NSIAD.  First, 371 
as in our case, it provided validation for the patient, who had suffered many years of 372 
intermittent symptoms for which no cause had been attributed.  Second, it provided a rationale 373 
for management.  Moderate fluid restriction has markedly improved his quality of life and he 374 
has been issued with ‘sick day rules’, advising close clinical and biochemical monitoring (i.e. 375 
fluid input/output charting with periodic measurement of serum/plasma sodium) in the event 376 
of intercurrent illness such as fevers, vomiting or diarrhoea; or hospitalisation, where medical 377 
staff must be alerted to the potential dangers of fluid overload. The genetic diagnosis also 378 
offers the possibility of screening family members and the involvement of a genetics service 379 
to discuss potential implications for family planning.  Importantly, genotyping may also guide 380 
therapeutic choices, e.g. use of a vaptan in the context of a ‘responsive mutation’.  381 
 382 
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Figure legends 528 
 529 
Fig 1.  a Sequence alignment of AVPR2 across several species, demonstrating conservation 530 
of the Arg137 residue within the DRY/H domain of the GPCR second intracellular loop.  b In 531 
silico crystallographic modelling showing the position of wild type (Arg137 - cyan) and 532 
mutant (Cys137 - orange) residues in the second transmembrane domain of AVPR2.  c 533 
Magnified view demonstrating the putative hydrogen bond (dotted line) between Arg137 and 534 
Thr269 (green) in the wild-type receptor, which is absent in the presence of the p.Arg137Cys 535 
mutation (orange).  536 
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Powlson et al Table 1 
 
Table 1. Water load test in proband 
Time Urine   VBG  Serum  Serum  Capillary Serum  Serum  Serum  Urine  Plasma 
 output  sodium  sodium  potassium glucose  urea  creatinine osmolality osmolality AVP 
(min) (mL/h)  (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (µmol/L) (mOsm/kg) (mOsm/kg) (pmol/L) 
0 -  133.9  129  3.9  5.4  4.2  88  274  805  0.9 
60 100  130.9  131  4.4  5.8  4.8  92  272  836  0.5 
120 50  130.2  129  3.9  6.0  4.8  -  266  745  0.4 
180* 40  125.3  -  -  6.0  -  -  -  808  0.8 
240 40  129.4  127  3.8  5.6  4.0  82  266  833  0.8 
300 30  128.9  129  4.1  -  4.2  90  -  845  0.6 
360 20  129.7  128  3.8  -  4.8  93  266  840  - 
 
Key: Following baseline measurements (0 min), 20 mL/kg of water (=1510 mL) was ingested over 15 min; AVP, arginine vasopressin; VBG, venous blood gas sample; * denotes 
serum sample haemolysed at this time point. 
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H.sapiens QMVGMYASSYMILAMTLD R HRAICRPMLAYRHGSGAHWNR
P.troglodytes QMVGMYASSYMILAMTLD R HRAICRPMLAYRHGSGAHWNR
M.mulatta QMVGMYASSYMILAMTLD R HRAICRPMLAYRHGGGAHWNR
C.lupus QMVGMYASSYMILAMTLD R HRAICRPMLAYRHGGGARWNR
B.taurus QMVGMYASSYMILAMTLD R HRAICRPMLAHRHGGGTHWNR
M.musculus QMVGMYASSYMILAMTLD R HRAICRPMLAYRHGGGARWNR
R.norvegicus QMVGMYASSYMILAMTLD R HRAICRPMLAYRHGGGARWNR
D.rerio QIVGMFASSYMIVAMTVD R HYAICCPLQAYRGGATSRWNT
X.tropicalis QVVGMYASSYMIVAMTFD R HQAICRPMMTFKKGS-ARWNI
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